Table 2.
Enriched gene ontology (GO) functions and KEGG pathways for the upregulated and downregulated genes.
| Enriched gene ontology functions for the upregulated genes | ||||
|---|---|---|---|---|
| Annotation Cluster 1 | Enrichment Score: 10.79 | Count | P-value | Benjamini |
| Category | Term | |||
| UP_KEYWORDS | Cell cycle 1 | 90 | 5.97E-17 | 5.01E-14 |
| UP_KEYWORDS | Cell division 1 | 59 | 6.10E-13 | 9.16E-11 |
| UP_KEYWORDS | Mitosis 1 | 46 | 1.99E-12 | 2.24E-10 |
| GOTERM_BP_DIRECT | Cell division (GO:0051301) | 48 | 2.95E-08 | 1.00E-04 |
| GOTERM_BP_DIRECT | Mitotic nuclear division 1 (GO:0007067) | 36 | 5.26E-07 | 4.47E-04 |
| Enriched KEGG pathways for the upregulated genes | ||||
| Category | Term | Count | P -value | Benjamini |
| KEGG_PATHWAY | Cell cycle 1 (hsa04110) | 25 | 1.16.E-07 | 3.01E-05 |
| KEGG_PATHWAY | p53 signaling pathway (hsa04115) | 13 | 3.85.E-04 | 4.87E-02 |
| KEGG_PATHWAY | Progesterone-mediated oocyte maturation (hsa04914) | 14 | 1.34.E-03 | 1.09E-01 |
| KEGG_PATHWAY | Oocyte meiosis (hsa04114) | 16 | 1.39.E-03 | 8.64E-02 |
| KEGG_PATHWAY | Transcriptional misregulation in cancer (hsa05202) | 20 | 3.61.E-03 | 1.71E-01 |
| KEGG_PATHWAY | Malaria (hsa05144) | 9 | 6.44.E-03 | 2.43E-01 |
| KEGG_PATHWAY | Jak-STAT signaling pathway (hsa04630) | 17 | 9.17.E-03 | 2.89E-01 |
| KEGG_PATHWAY | Biosynthesis of amino acids (hsa01230) | 11 | 9.59.E-03 | 2.68E-01 |
| Enriched gene ontology functions for the downregulated genes | ||||
| Annotation Cluster 1 | Enrichment Score: 28.63 | Count | P-value | Benjamini |
| Category | Term | |||
| INTERPRO | Cadherin, N-terminal (IPR013164) | 42 | 1.05E-35 | 1.61E-32 |
| UP_SEQ_FEATURE | domain:Cadherin 6 | 46 | 1.54E-35 | 4.90E-32 |
| UP_SEQ_FEATURE | domain:Cadherin 5 | 49 | 2.59E-33 | 4.11E-30 |
| UP_SEQ_FEATURE | domain:Cadherin 2 | 50 | 3.39E-32 | 3.59E-29 |
| UP_SEQ_FEATURE | domain:Cadherin 1 | 50 | 3.39E-32 | 3.59E-29 |
| UP_SEQ_FEATURE | domain:Cadherin 4 | 49 | 1.05E-31 | 8.32E-29 |
| UP_SEQ_FEATURE | domain:Cadherin 3 | 49 | 1.05E-31 | 8.32E-29 |
| INTERPRO | Cadherin (IPR002126) | 49 | 7.89E-30 | 6.03E-27 |
| INTERPRO | Cadherin conserved site (IPR020894) | 48 | 9.35E-30 | 4.77E-27 |
| INTERPRO | Cadherin-like (IPR015919) | 49 | 1.98E-29 | 7.56E-27 |
| SMART | Cadherin repeats (SM00112) | 49 | 6.76E-28 | 2.18E-25 |
| UP_KEYWORDS | Cell adhesion 2 | 92 | 1.86E-27 | 8.65E-25 |
| GOTERM_BP_DIRECT | Homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156) | 53 | 3.02E-26 | 1.06E-22 |
| UP_KEYWORDS | Calcium | 121 | 1.12E-22 | 1.74E-20 |
| GOTERM_MF_DIRECT | Calcium ion binding (GO:0005509) | 95 | 1.07E-14 | 1.21E-11 |
| Annotation Cluster 2 | Enrichment Score: 13.91 | Count | P-value | Benjamini |
| Category | Term | |||
| UP_KEYWORDS | Cell membrane 3 | 294 | 1.20E-24 | 2.79E-22 |
| GOTERM_CC_DIRECT | plasma membrane (GO:0005886) | 351 | 5.24E-20 | 2.89E-17 |
| UP_SEQ_FEATURE | glycosylation site:N-linked (GlcNAc) | 342 | 4.47E-18 | 2.84E-15 |
| UP_KEYWORDS | Glycoprotein | 358 | 4.52E-18 | 5.26E-16 |
| UP_KEYWORDS | Membrane | 520 | 5.24E-16 | 5.17E-14 |
| UP_SEQ_FEATURE | topological domain:Extracellular | 238 | 2.10E-14 | 9.52E-12 |
| GOTERM_CC_DIRECT | integral component of plasma membrane (GO:0005887) | 146 | 1.27E-13 | 3.50E-11 |
| UP_SEQ_FEATURE | topological domain:Cytoplasmic | 273 | 1.59E-12 | 5.60E-10 |
| UP_KEYWORDS | Transmembrane | 396 | 1.05E-11 | 8.15E-10 |
| UP_KEYWORDS | Transmembrane helix | 394 | 1.64E-11 | 1.09E-09 |
| UP_SEQ_FEATURE | transmembrane region | 362 | 5.12E-11 | 1.63E-08 |
| GOTERM_CC_DIRECT | integral component of membrane (GO:0016021) | 334 | 4.06E-04 | 3.66E-02 |
| Enriched KEGG pathways for the downregulated genes | ||||
| Category | Term | Count | P-value | Benjamini |
| KEGG_PATHWAY | Natural killer cell mediated cytotoxicity (hsa04650) | 19 | 1.76.E-04 | 4.55.E-02 |
| KEGG_PATHWAY | cAMP signaling pathway (hsa04024) | 24 | 8.63.E-04 | 1.08.E-01 |
| KEGG_PATHWAY | cGMP-PKG signaling pathway (hsa04022) | 20 | 2.82.E-03 | 2.21.E-01 |
| KEGG_PATHWAY | Hematopoietic cell lineage 3 (hsa04640) | 13 | 3.04.E-03 | 1.83.E-01 |
| KEGG_PATHWAY | Amphetamine addiction (hsa05031) | 11 | 3.95.E-03 | 1.89.E-01 |
| KEGG_PATHWAY | Tuberculosis (hsa05152) | 20 | 5.74.E-03 | 2.24.E-01 |
| KEGG_PATHWAY | Cocaine addiction (hsa05030) | 9 | 6.07.E-03 | 2.06.E-01 |
| KEGG_PATHWAY | Neuroactive ligand-receptor interaction (hsa04080) | 27 | 8.29.E-03 | 2.41.E-01 |
| KEGG_PATHWAY | Insulin secretion (hsa04911) | 12 | 8.65.E-03 | 2.26.E-01 |
| KEGG_PATHWAY | Adrenergic signaling in cardiomyocytes (hsa04261) | 17 | 8.91.E-03 | 2.11.E-01 |
1The underlined terms include PLK1. 2The underlined term includes EPHA4. 3The underlined terms include MS4A1 (CD20) and MS4A7.